Learn how CGRP first line migraine prevention guidelines are shifting, what this means for patients, and what to track to support your treatment decisions.
For years, people seeking preventive treatment for migraine often had to work through a long queue of medications, many developed for other conditions, before a CGRP-targeted therapy was considered. That queue is shrinking. Updated guidance on CGRP first line migraine prevention is shifting the conversation, and for many patients it means a shorter, more direct path to treatments designed specifically for migraine biology.
This article explains what first-line status actually means, why CGRP mechanisms are particularly well suited for prevention, and what you can do right now to prepare for a productive conversation with your clinician.
CGRP (calcitonin gene-related peptide) is a protein that plays a central role in triggering migraine attacks. During an attack, CGRP levels rise sharply in the trigeminal pathway, contributing to the pain and inflammation that defines a migraine. Preventive therapies targeting this pathway work either by blocking CGRP itself or by blocking the receptors it binds to.
This specificity matters. Older preventive medications, including certain blood pressure drugs, antiepileptics, and antidepressants, can reduce migraine frequency, but they were not built for migraine. Their mechanisms are broad, which is why they come with side effect profiles that affect the cardiovascular system, mood, weight, and cognition. CGRP-targeted therapies act on a pathway specific to migraine, which is why tolerance is generally better for many patients.
Until recently, most clinical guidelines positioned CGRP-targeted preventives as a second- or third-line option. The reasoning was partly practical: these therapies were newer, expensive, and required prior authorization from insurers. Prescribers had to document that a patient had already tried and failed other agents first.
Updated guidance from headache medicine specialists now supports considering CGRP-targeted prevention earlier, particularly for patients who:
The shift is supported by a growing body of evidence showing that starting the right prevention sooner reduces the cumulative burden of migraine and lowers the risk of progression from episodic to chronic migraine. Understanding the difference between episodic and chronic migraine is one of the first steps in knowing where you stand.
First-line status in clinical guidelines means a treatment is appropriate to try from the beginning, without requiring that other treatments fail first. It does not mean:
Guideline status gives your prescriber stronger ground to advocate for you, especially during insurance reviews. But the final decision always involves your full clinical picture, your history with other medications, and what your insurer covers. Only your clinician can determine what is appropriate for your situation.
Preparation changes the outcome of a prevention conversation. Clinicians make better decisions with better data. Here is what to bring:
1. A migraine diary
Record attack dates, duration, severity, and any factors you noticed before or during attacks. Consistent tracking over at least 4 to 8 weeks gives your clinician a real picture of your pattern. The migraine triggers tracking guide walks through what to log and how.
2. A disability score
Disability tools like MIDAS and HIT-6 quantify how much migraine affects your ability to function at work, home, and socially. These scores are not just useful for you to understand your own situation; they are part of the clinical record. You can complete the MIDAS calculator or the HIT-6 calculator before your appointment and bring the results. The MIDAS and HIT-6 explainer covers what each score measures and why clinicians use them.
3. Your preventive medication history
List every preventive you have tried, the dose if you remember it, how long you took it, and why you stopped. This is exactly the kind of documentation that supports a case for moving to CGRP-targeted prevention.
4. A note on monthly migraine days
Monthly migraine days (MMDs) are one of the most commonly used measures to classify migraine severity and track treatment response. Understanding what monthly migraine days mean helps you frame your experience in the terms your clinician uses.
If your clinician starts a preventive therapy, tracking does not stop. CGRP-targeted prevention typically takes 2 to 3 months to reach full effect, and the metrics you track before starting become your baseline for comparison.
Key things to monitor:
The measuring CGRP progress guide explains what a meaningful response looks like and how to document it in a way that supports continued insurance coverage and treatment decisions.
One area to watch is medication overuse. If acute treatments are used too frequently, they can contribute to more frequent headaches, a pattern described in the medication overuse headache article. Preventive treatment is partly aimed at reducing acute medication use, so tracking both gives you a clearer picture of how you are responding.
Migraine care improves when clinicians have accurate, longitudinal data. A consistent log, completed before and during prevention, is the most concrete thing you can do to support your own treatment.
The Migraine Tracker: CGRP Log app is built around this kind of structured tracking, covering attack frequency, severity, and the patterns that matter most for prevention conversations. The data you collect there is easy to share with your clinician, which is covered in the sharing your migraine log with your doctor guide.
As always, talk to your doctor, neurologist, or headache specialist before starting, stopping, or changing any preventive treatment. Guidelines provide a framework; your clinician applies that framework to your specific situation.
Educational, not medical advice. Migraine Tracker: CGRP Log is a personal tracking tool, not a medical device. It does not diagnose, treat, or provide medical advice. Always talk to your clinician.
First-line means a treatment is considered appropriate to try before moving to other options. For migraine prevention, updated guidance increasingly supports using CGRP-targeted therapies early rather than only after multiple older medications have failed.
CGRP vs Botox for migraine: how each works, who qualifies, and what to track to help your doctor choose the right prevention approach.
Understand what to do if CGRP medication doesn't work, why partial or no response happens, and what questions to bring to your neurologist.
Wondering how long does it take for CGRP medication to work? Learn the typical timeline, what to track each month, and when to talk to your neurologist.
